The immuno-oncological challenge of COVID-19
- PMID: 35121872
- DOI: 10.1038/s43018-020-00122-3
The immuno-oncological challenge of COVID-19
Erratum in
-
Author Correction: The immuno-oncological challenge of COVID-19.Nat Cancer. 2022 Mar;3(3):371. doi: 10.1038/s43018-022-00342-9. Nat Cancer. 2022. PMID: 35136234 Free PMC article. No abstract available.
Abstract
Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.
© 2020. Springer Nature America, Inc.
References
-
- World Health Organization. Coronavirus Disease (COVID-19) Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... (accessed 15 August 2020).
-
- Worldometer. Coronavirus Update (Live): 24,643,164 cases and 835,843 deaths from COVID-19 virus pandemic. Worldometer. https://www.worldometers.info/coronavirus/ (accessed 15 August 2020).
-
- Choi, S.-Y., Bertram, S., Glowacka, I., Park, Y. W. & Pöhlmann, S. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol. Med. 15, 303–312 (2009).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
